Biosimilar Monoclonal Antibodies (mAbs) Market Analysis 2024

1. Downloaded from: justpaste.it/4w3ut Biosimilar Monoclonal Antibodies (mAbs) Market Demand, Size and Report 2024 The biosimilar monoclonal antibodies market size has the potential to grow by USD 8.65 billion during 2020-2024, and the market’s growth momentum will accelerate during the forecast period because of the steady increase in year-over-year growth. Get Sample of the Report: https://www.technavio.com/talk-to-us? report=IRTNTR41616&type=sample&src=report This report provides a detailed analysis of the market by application (cancer and non-cancer) and geography (Asia, Europe, North America, and ROW). Also, the report analyzes the market’s competitive landscape. It offers information on several market vendors, including Amgen Inc., BIOCAD, Biocon Ltd., BioXpress Therapeutics SA, Boehringer Ingelheim International GmbH, Celltrion Inc., Coherus BioSciences Inc., Intas Pharmaceuticals Ltd., Novartis AG, and Pfizer Inc. Market Competitive Analysis The biosimilar monoclonal antibodies market is concentrated. Most vendors operating in this market rely on their in-house capabilities to manufacture active pharmaceutical ingredients for the development of high-quality and safe biosimilar mAbs. Several vendors in the market are developing biosimilar mAbs to leverage the patent expiry of major mAbs such as trastuzumab, rituximab, adalimumab, and infliximab, which are indicated to treat various chronic diseases. The presence of a strong pipeline with late-stage molecules that are expected to launch during the forecast period has encouraged the entry of new players. The key vendors in the market are focusing on R&D activities and product development to expand their geographical reach and increase their market share. Amgen Inc., BIOCAD, and Biocon Ltd. are some of the major market participants. Although the increase in the number of expiring patents of blockbuster mAbs will offer immense growth opportunities, the presence of stringent regulatory policies will challenge the growth of the market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments. To help clients improve their market position, this biosimilar monoclonal antibodies market forecast report provides a detailed analysis of the market leaders. It offers information on the competencies and capacities of these companies. The report also covers details on the market’s competitive landscape and provides information on the products offered by various companies. Moreover, this biosimilar monoclonal antibodies market analysis report also includes information on the upcoming trends and challenges that will influence market growth. This will help companies create strategies to make the most of future growth opportunities. Biosimilar Monoclonal Antibodies Market: Key Drivers and Trends The increasing prevalence of chronic diseases globally has become a serious public health concern. The common types of cancer were breast cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, lung and

2. bronchus cancer, bladder cancer, kidney and renal pelvis cancer, endometrial cancer, leukemia, pancreatic cancer, thyroid cancer, non-Hodgkin lymphoma, and liver cancer. Furthermore, in Canada, an estimated 0.59% of new cancer cases were expected to occur in 2019. Similarly, in Europe and Asia, the prevalence of cancer is high. For instance, according to the OECD, in 2018, 3 million new cases of cancer were diagnosed in the European Union. The most common types of cancer were breast cancer (13.5%), prostate cancer (12.5%), colon and rectum cancer (12.3%), and lung cancer (12.2%). Also, globally, the prevalence of autoimmune diseases is high. As per the Centers for Disease Control and Prevention (CDC), in 2017, 54.4 million adults in the US had arthritis, which accounted for about 25% of the population. As the treatment costs of these diseases are high, the development of cost-effective therapeutics becomes imperative. As biosimilar mAbs are a cost-effective option, their demand from patients is increasing. Factors such as the rising prevalence of chronic diseases, patent expiry of several blockbuster therapeutics, coupled with the high cost of therapeutics, have led to an increase in the demand for cost-effective biosimilar mAbs. This has encouraged vendors operating in the market to develop biosimilar mAbs. The market is witnessing a rise in the number of approvals for several biosimilar mAbs, which will drive the growth of the market during the forecast period. Such factors will drive biosimilar mAbs market growth at a CAGR of over 30%. Biosimilar Monoclonal Antibodies Market: Key Highlights of the Report for 2020-2024 CAGR of the market during the forecast period 2020-2024 Detailed information on factors that will drive biosimilar monoclonal antibodies market growth during the next five years Precise estimation of the biosimilar monoclonal antibodies market size and its contribution to the parent market Accurate predictions on upcoming trends and changes in consumer behavior The growth of the biosimilar monoclonal antibodies market industry across Asia, Europe, North America, and ROW A thorough analysis of the market’s competitive landscape and detailed information on vendors Comprehensive details of factors that will challenge the growth of biosimilar monoclonal antibodies market vendors